Aurobindo Pharma Subsidiary Secures European Commission Approval
CuraTeQ Biologics, the wholly owned step-down subsidiary of Aurobindo Pharma Ltd, on 2 July announced that it has obtained marketing authorisation from the European Commission for its trastuzumab biosimilar, Dazublys. This approval follows the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issuing a positive opinion in April 2025, recommending Dazublys…